BACKGROUND AND PURPOSE: Several anticancer drugs with diverse chemical structures can induce differentiation of cancer cells. This study was undertaken to explore the potential contribution of caspase-3 to pharmacologically-induced differentiation of K562 cells. EXPERIMENTAL APPROACH: We assessed differentiation by measuring the expression of glycophorin A and haemoglobin synthesis in K562 cells treated with low concentrations of doxorubicin, hydroxyurea, cytosine arabinoside, cisplatin and haemin. Caspase-3 activation, mitochondrial membrane potential dissipation and viability were assessed by FACS. GATA-1-binding activity was evaluated by EMSA. KEY RESULTS: Treatment of K562 cells with low concentrations of the tested drugs activated caspase-3 but did not trigger detectable apoptosis. Instead, elevated levels of haemoglobin-positive and glycophorin A/caspase-3-double-positive cells were observed, suggesting involvement of caspase-3 in drug-induced differentiation. Inhibition of caspase-3 activity significantly reduced the ability of K562 cells to execute the differentiation programme. Mitochondrial membrane potential dissipation was observed, indicating involvement of the mitochondrial pathway. Binding activity of GATA-1, transcription factor responsible for differentiation and cell survival, was not diminished by increased caspase-3 activity during drug-stimulated differentiation. CONCLUSIONS AND IMPLICATIONS: Our results could explain how anticancer drugs, with diverse structures and modes of action, can stimulate erythroid differentiation in leukaemic cells with appropriate genetic backgrounds. Our findings imply that some similarities exist between pharmacologically-induced differentiation of erythroleukaemic cells and normal erythropoiesis, both involving caspase-3 activation at high levels of anti-apoptotic protein Bcl-X(L) and chaperone protein Hsp70 (heat shock protein 70). Therefore, the functions of caspase-3, unrelated to cell death, can be extended to pharmacologically-induced differentiation of some cancer cells.
BACKGROUND AND PURPOSE: Several anticancer drugs with diverse chemical structures can induce differentiation of cancer cells. This study was undertaken to explore the potential contribution of caspase-3 to pharmacologically-induced differentiation of K562 cells. EXPERIMENTAL APPROACH: We assessed differentiation by measuring the expression of glycophorin A and haemoglobin synthesis in K562 cells treated with low concentrations of doxorubicin, hydroxyurea, cytosine arabinoside, cisplatin and haemin. Caspase-3 activation, mitochondrial membrane potential dissipation and viability were assessed by FACS. GATA-1-binding activity was evaluated by EMSA. KEY RESULTS: Treatment of K562 cells with low concentrations of the tested drugs activated caspase-3 but did not trigger detectable apoptosis. Instead, elevated levels of haemoglobin-positive and glycophorin A/caspase-3-double-positive cells were observed, suggesting involvement of caspase-3 in drug-induced differentiation. Inhibition of caspase-3 activity significantly reduced the ability of K562 cells to execute the differentiation programme. Mitochondrial membrane potential dissipation was observed, indicating involvement of the mitochondrial pathway. Binding activity of GATA-1, transcription factor responsible for differentiation and cell survival, was not diminished by increased caspase-3 activity during drug-stimulated differentiation. CONCLUSIONS AND IMPLICATIONS: Our results could explain how anticancer drugs, with diverse structures and modes of action, can stimulate erythroid differentiation in leukaemic cells with appropriate genetic backgrounds. Our findings imply that some similarities exist between pharmacologically-induced differentiation of erythroleukaemic cells and normal erythropoiesis, both involving caspase-3 activation at high levels of anti-apoptotic protein Bcl-X(L) and chaperone protein Hsp70 (heat shock protein 70). Therefore, the functions of caspase-3, unrelated to cell death, can be extended to pharmacologically-induced differentiation of some cancer cells.
Authors: Jun Fujita; Ana M Crane; Marlon K Souza; Marion Dejosez; Michael Kyba; Richard A Flavell; James A Thomson; Thomas P Zwaka Journal: Cell Stem Cell Date: 2008-06-05 Impact factor: 24.633
Authors: N Bianchi; F Ongaro; C Chiarabelli; L Gualandi; C Mischiati; P Bergamini; R Gambari Journal: Biochem Pharmacol Date: 2000-07-01 Impact factor: 5.858
Authors: C Oetzel; T Jonuleit; A Götz; H van der Kuip; H Michels; J Duyster; M Hallek; W E Aulitzky Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: L Galluzzi; N Joza; E Tasdemir; M C Maiuri; M Hengartner; J M Abrams; N Tavernarakis; J Penninger; F Madeo; G Kroemer Journal: Cell Death Differ Date: 2008-02-29 Impact factor: 15.828
Authors: Andreas Koenig; Karen A Fortner; Benjamin R King; Jonathan Madden; Iwona A Buskiewicz; Ralph C Budd Journal: Immunology Date: 2012-04 Impact factor: 7.397
Authors: Maxime Mioulane; Gabor Foldes; Nadire N Ali; Michael D Schneider; Sian E Harding Journal: J Cardiovasc Transl Res Date: 2012-08-16 Impact factor: 4.132